

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	ingenol
Brand Name	Picato®
Dosage Form(s)	0.015% and 0.05% topical gel
Manufacturer	Leo Pharma Inc.
Submission Review	New Submission
Use Reviewed	Treatment of actinic keratosis (AK)
Common Drug Review (CDR)	Yes, CDR recommended to: Do not list, Visit CDR website for more details: http://www.cadth.ca/media/cdr/complete/SR0330_complete_Picato-30-Jan-14.pdf
Drug Benefit Council (DBC)	No
Drug Coverage Decision	Non-Benefit
Date	June 5, 2014
Reason(s)	<ul style="list-style-type: none"> Ingenol was submitted by the manufacturer for review as a second line therapy after patients fail or are intolerant to 5-fluorouracil (5-FU), which another drug for the treatment of actinic keratosis. CDR recommended not to list ingenol because clinical evidence does not support use of this product as a second line product and it is more costly than 5-FU. Ingenol was compared to a vehicle (a non-drug) in clinical studies rather than other drugs used in the treatment of actinic keratosis. DBC did not review ingenol because it was a 'Do Not List' recommendation by the CDR.
Other Information	Ingenol Request for Advice submission is currently under review by the CDR and once the review is completed, the Ministry of Health will review ingenol again.

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.